Join the Diabetes, Type 2 group to help and get support from people like you.
Diabetes, Type 2 News
Related terms: Noninsulin-dependent Diabetes, Type 2 Diabetes, Diabetes, Type 2
Exercise at One Time of Day Might Be Best for Blood Sugar Control
WEDNESDAY, June 11, 2024 – Folks trying to control their blood sugar levels might do best to work out in the evening, a new study suggests. Exercise performed between 6 p.m. and midnight appeared to...
Insulin-Treated T2D Patients Unwilling to Participate in Intensive Lifestyle Intervention
MONDAY, June 10, 2024 – For adults with advanced, insulin-treated type 2 diabetes (T2D), willingness to participate in an intensive lifestyle intervention (ILI) is very low, according to a research...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
Diabetes Tied to Higher Prevalence of Overactive Bladder
TUESDAY, June 4, 2024 – Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in Endocrinology. Qingliu He, from ...
GLP-1 Weight Loss Meds Might Keep Your Pancreas Healthy
MONDAY, June 3, 2024 – Ozempic and Wegovy might help lower the risk of pancreatitis in patients with obesity and type 2 diabetes, a new study says. Up to now, doctors have been cautious about...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 – For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from cardiovascular causes,...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 – Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation, according to a research...
Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes
FRIDAY, May 24, 2024 – Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug significantly reduces the...
Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds
THURSDAY, May 23, 2024 – Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from first use more than...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Related drug support groups
metformin, Ozempic, Victoza, Lantus, Mounjaro, Trulicity, glipizide, semaglutide, Rybelsus, view more... Jardiance, Lantus Solostar, Humalog, Farxiga, Novolog, Janumet, insulin glargine, Januvia, insulin lispro, Bydureon, Tresiba, Levemir, liraglutide, Invokana, Glucophage, Humulin N, insulin degludec